Search SciPol

Brought to you by
April 17, 2018 10:00 am - April 17, 2018 4:00 pm

Meeting: FDA Patient-Focused Drug Development for Opioid Use Disorder

  • Government
  • Agency
  • Neuroscience

The Food and Drug Administration (FDA) is hosting a public meeting on Patient-Focused Drug Development for Opioid Use Disorder (OUD), in collaboration with National Institute of Drug Abuse (NIDA). In addition to NIDA, FDA is also working closely with patient advocacy and community organizations to encourage participation from individuals with OUD. This meeting aligns with FDA’s ongoing work aimed at reducing the impact of opioid abuse and addiction.

In particular, FDA is interested in learning patients’ perspectives on OUD, including the effects on their health and well-being that have the greatest impact on daily life, their experience using prescription medical treatments and other treatments or therapies for OUD, and challenges or barriers to accessing or using medical treatments for OUD.

Information on how to register for the meeting and the location is available at the FDA website